Bevacizumab intravítreo en el tratamiento de la neovascularización subretiniana secundaria a rotura coroidea

Translated title of the contribution: Use of intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to choroidal rupture

X. Valldeperas, R. Bonilla, M. R. Romano, J. De La Cámara

Research output: Contribution to journalArticle

Abstract

Case report: A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C 3F 8 and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) that was treated with intravitreal bevacizumab. One year after a single bevacizumab injection the CNV remained inactive, with a final VA of 0.5. Discussion: Intravitreal bevacizumab injection is a new and effective treatment for traumatic CNV. In our patient, in contrast to other aetiologies, the CNV needed no more than one Avastin ® injection to be inactivated, after one year of follow-up.

Translated title of the contributionUse of intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to choroidal rupture
Original languageSpanish
Pages (from-to)380-383
Number of pages4
JournalArchivos de la Sociedad Espanola de Oftalmologia
Volume86
Issue number11
DOIs
Publication statusPublished - Nov 2011

Keywords

  • Bevacizumab
  • Choroidal neovascularisation
  • Choroidal rupture
  • Ocular traumatism
  • Pneumatic displacement
  • Recombinant tissue plasminogen activator (rTPA)
  • Submacular haemorrhage

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Use of intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to choroidal rupture'. Together they form a unique fingerprint.

  • Cite this